Eli Lilly and Company (NYSE: LLY) broke ground today in Houston, Texas, one of ten U.S. manufacturing sites — and fifth ...
Phase 3 trials of barzolvolimab show significant efficacy in chronic spontaneous urticaria; BLA submission expected in 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results